Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.
Tamoxifen was granted FDA approval on 30 December 1977.
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
- Conditions
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Andrea DeCensi
- Target Recruit Count
- 500
- Registration Number
- NCT01357772
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo studio e la cura dei tumori, Meldola, Forlì-Cesena, Italy
🇮🇹Ospedali riuniti ASL AL - Ospedale SS. Antonio e Margherita, Tortona, Alessandria, Italy
🇮🇹Ospedale di Carpi "Bernardino Ramazzini", Carpi, Modena, Italy
Adjuvant AI Combined With Zoladex
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 670
- Registration Number
- NCT01352091
- Locations
- 🇨🇳
FUSCC, Shanghai, Shanghai, China
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 111
- Registration Number
- NCT01298713
- Locations
- 🇫🇷
Hopital Hotel Dieu, Paris, France
Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Nazem Atassi
- Target Recruit Count
- 60
- Registration Number
- NCT01257581
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸University of Massachusetts Medical Center, Worcester, Massachusetts, United States
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Institut Cancerologie de l'Ouest
- Target Recruit Count
- 140
- Registration Number
- NCT01220076
- Locations
- 🇫🇷
Centre Léon Berard, Lyon, France
🇫🇷Institut de Cancerologie de l'Ouest (ICO), Saint Herblain, France
🇫🇷Institut Curie, Paris, France
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01189500
- Locations
- 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2010-07-26
- Lead Sponsor
- Yonsei University
- Registration Number
- NCT01169792
- Locations
- 🇰🇷
Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Jin-Gu, Busan, Korea, Republic of
🇰🇷Department of Surgery, Yonsei University College of Medicine, Saedaemoon-gu, Seoul, Korea, Republic of
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 124
- Registration Number
- NCT01124695
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- Western Sydney Local Health District
- Target Recruit Count
- 121
- Registration Number
- NCT01075802
- Locations
- 🇦🇺
St George Hospital, Sydney, New South Wales, Australia
🇦🇺Westmead Cancer Care Centre, Westmead, New South Wales, Australia
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 59
- Registration Number
- NCT01027416
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.